ECSP055911A - Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación - Google Patents

Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación

Info

Publication number
ECSP055911A
ECSP055911A EC2005005911A ECSP055911A ECSP055911A EC SP055911 A ECSP055911 A EC SP055911A EC 2005005911 A EC2005005911 A EC 2005005911A EC SP055911 A ECSP055911 A EC SP055911A EC SP055911 A ECSP055911 A EC SP055911A
Authority
EC
Ecuador
Prior art keywords
antineoplassic
effectiveness
agents
improve
protein kinase
Prior art date
Application number
EC2005005911A
Other languages
English (en)
Inventor
Sacha Ninkovic
Michael John Bennett
Eugene Yuanjin Rui
Fen Wang
Suzanne Pritchett Benedict
Min Teng
Yong Wang
Jinjiang Zhu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP055911A publication Critical patent/ECSP055911A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

. Proteína quinasas, tales como CHK-1, que inhiben compuestos tricíclicos de la siguiente fórmula (en la que R2, R3 y R4 son como se han definido en la memoria descriptiva) composiciones farmacéuticas que contienen cantidades eficaces de dichos compuestos o sus sales son útiles como un único agente o en combinación con un agente anti-neoplásico o radiación terapéutica que tienen un efecto anti-neoplásico para tratar enfermedades o afecciones tales como cánceres.
EC2005005911A 2003-01-09 2005-07-08 Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación ECSP055911A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09

Publications (1)

Publication Number Publication Date
ECSP055911A true ECSP055911A (es) 2005-11-22

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005911A ECSP055911A (es) 2003-01-09 2005-07-08 Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación

Country Status (34)

Country Link
US (3) US6967198B2 (es)
EP (2) EP1585749B1 (es)
JP (1) JP3990718B2 (es)
KR (1) KR100697746B1 (es)
CN (1) CN1759118B (es)
AP (1) AP2048A (es)
AT (1) ATE404564T1 (es)
AU (1) AU2004203977B2 (es)
BR (1) BRPI0406701A (es)
CA (1) CA2512683C (es)
CR (1) CR7899A (es)
CY (1) CY1108408T1 (es)
DE (1) DE602004015724D1 (es)
DK (1) DK1585749T3 (es)
EA (1) EA009337B1 (es)
EC (1) ECSP055911A (es)
ES (1) ES2309484T3 (es)
GE (1) GEP20084367B (es)
HR (1) HRP20050624A2 (es)
IL (1) IL169082A (es)
IS (1) IS7884A (es)
MA (1) MA27703A1 (es)
MX (1) MXPA05007352A (es)
NO (1) NO20053775L (es)
NZ (1) NZ540638A (es)
OA (1) OA13017A (es)
PL (1) PL378372A1 (es)
PT (1) PT1585749E (es)
RS (1) RS20050522A (es)
SI (1) SI1585749T1 (es)
TN (1) TNSN05176A1 (es)
UA (1) UA80733C2 (es)
WO (1) WO2004063198A1 (es)
ZA (1) ZA200504674B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2473886C (en) * 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
EA009337B1 (ru) * 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
JP2008530575A (ja) * 2005-02-18 2008-08-07 アストラゼネカ アクチボラグ Ｃｈｋ１阻害薬に対する応答性を判定する方法
JP5117374B2 (ja) 2005-03-29 2013-01-16 イコス・コーポレイション Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ZA200800314B (en) 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
AU2006279541A1 (en) 2005-08-15 2007-02-22 The Regents Of The University Of California VEGF-activated FAS ligands
WO2007023948A1 (ja) 2005-08-25 2007-03-01 Ube Industries, Ltd. 光学活性（Ｓ又はＲ）－α－アミノ酸及び光学活性（Ｒ又はＳ）－α－アミノ酸エステルの製造方法
EP1916896A4 (en) * 2005-08-26 2010-08-11 Univ California NOT STEROID-antiandrogens
CN101415417A (zh) * 2006-04-04 2009-04-22 辉瑞产品公司 (2r,z)-2-氨基-2-环己基-n-(5-(1-甲基-1h-吡唑-4-基)-1-氧代-2,6-二氢-1h-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺的组合疗法
WO2007113647A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
EP2086644A2 (en) * 2006-11-17 2009-08-12 Schering Corporation Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
JP5576370B2 (ja) * 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
EP2346881A1 (en) * 2008-10-10 2011-07-27 Priaxon AG Novel compounds which modulate kinase activity
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
KR101716012B1 (ko) * 2011-12-31 2017-03-13 베이진 엘티디 Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 다이하이드로다이아제피노카르바졸론
KR101684039B1 (ko) 2011-12-31 2016-12-07 베이진 엘티디 Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 피리도프탈라지논
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
AU2016312011B2 (en) * 2015-08-25 2021-02-04 Beigene, Ltd. Process for preparing Parp inhibitor, crystalline forms, and uses thereof
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US11202782B2 (en) 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN110392687B (zh) 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
RU2764243C2 (ru) * 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3914284A4 (en) * 2019-01-25 2022-10-26 Numedii, Inc. METHODS OF TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
EP4067351B1 (en) 2019-11-29 2025-01-22 NovaOnco JS Therapeutics Co., Ltd. Diazaindole derivative and use thereof as chk1 inhibitor
WO2022011458A1 (en) * 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
AU2021318572A1 (en) * 2020-07-31 2023-02-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as PARP inhibitor and method for preparing same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
EP1140936B1 (en) * 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
JP4652648B2 (ja) 1999-08-27 2011-03-16 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアンチセンスオリゴヌクレオチド、およびその細胞トランスフェクション処方物
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
DE60019318T2 (de) 1999-09-22 2006-03-09 Canbas Co., Ltd., Numazu Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6887996B2 (en) 2000-12-01 2005-05-03 Guilford Pharmaceuticals Inc. Compounds and their use
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
EA009337B1 (ru) * 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии

Also Published As

Publication number Publication date
MA27703A1 (fr) 2006-01-02
TNSN05176A1 (fr) 2007-06-11
UA80733C2 (en) 2007-10-25
WO2004063198A1 (en) 2004-07-29
JP2006516274A (ja) 2006-06-29
EP1947102A1 (en) 2008-07-23
NZ540638A (en) 2007-12-21
PT1585749E (pt) 2008-10-23
NO20053775L (no) 2005-09-16
NO20053775D0 (no) 2005-08-08
GEP20084367B (en) 2008-05-13
JP3990718B2 (ja) 2007-10-17
EA200500893A1 (ru) 2006-02-24
CN1759118A (zh) 2006-04-12
US6967198B2 (en) 2005-11-22
US7462713B2 (en) 2008-12-09
KR20050092397A (ko) 2005-09-21
EP1585749A1 (en) 2005-10-19
SI1585749T1 (sl) 2008-10-31
CR7899A (es) 2005-08-05
AP2005003353A0 (en) 2005-09-30
ATE404564T1 (de) 2008-08-15
US20050075499A1 (en) 2005-04-07
PL378372A1 (pl) 2006-04-03
US20070135415A1 (en) 2007-06-14
US20060004052A1 (en) 2006-01-05
DE602004015724D1 (de) 2008-09-25
EA009337B1 (ru) 2007-12-28
CY1108408T1 (el) 2014-02-12
DK1585749T3 (da) 2008-09-22
CN1759118B (zh) 2010-12-08
CA2512683A1 (en) 2004-07-29
ZA200504674B (en) 2006-07-26
IL169082A (en) 2011-02-28
US7132533B2 (en) 2006-11-07
ES2309484T3 (es) 2008-12-16
OA13017A (en) 2006-11-10
CA2512683C (en) 2010-03-16
MXPA05007352A (es) 2006-02-17
IS7884A (is) 2005-06-09
HRP20050624A2 (en) 2006-02-28
AP2048A (en) 2009-09-24
HK1086257A1 (en) 2006-09-15
AU2004203977A1 (en) 2004-07-29
EP1585749B1 (en) 2008-08-13
RS20050522A (sr) 2007-12-31
BRPI0406701A (pt) 2005-12-20
KR100697746B1 (ko) 2007-03-22
AU2004203977B2 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
CR7899A (es) Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CR20110016A (es) Compuestos quimicos 251
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
DOP2004000949A (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos
PA8609201A1 (es) Piridinonas sustituidas
UY28271A1 (es) Compuestos químicos
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
UY28366A1 (es) Compuestos químicos
BR112023002295A2 (pt) Terapia de combinação
PA8720601A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevenciòn de trastornos psicoticos
GT200500026A (es) Derivados de beta-aminoacidos como inhibidores del factor xa.
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr
AR063819A1 (es) Pirrolo[1,2-a]imidazoldiona eficaz en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos. composiciones farmaceuticas y usos.